Gefitinib and Antacids: — The Interaction That Silently Reduces Absorption

Gelusil, ENO, and similar antacids raise the pH of your stomach temporarily, which can reduce gefitinib absorption if taken at the same time or close to it. Tell your oncologist you are using one. They may advise a specific gap between the antacid and your gefitinib tablet, or suggest an alternative for managing the acidity. Do not assume it is safe to take at any time without checking first.

The FDA label for gefitinib specifically notes that proton pump inhibitors like omeprazole significantly reduce how much drug is absorbed. These medicines suppress acid for many hours, so separating the doses by a few hours does not reliably solve the problem. Your oncologist needs to know if you are taking a PPI and may recommend switching to a different type of acid medicine, or reassess whether the PPI is still needed.

The FDA labelling documents a significant reduction in gefitinib exposure with proton pump inhibitors, but the clinical point matters more than any specific figure: the reduction is large enough that it may affect how well the treatment works. Response to treatment is assessed through imaging at intervals your oncologist will explain, not through routine drug-level testing. This is why your team needs to know about every acid medicine from the start of treatment.

For short-acting antacids like Gelusil, timing may help, and your oncologist may advise a specific gap before or after your gefitinib tablet. For proton pump inhibitors, timing is not a reliable solution because they suppress acid production across the whole day rather than just around the dose. H2 blockers fall in between — a timed separation may be possible, but the exact approach needs to be agreed with your oncologist, not worked out independently.

Not necessarily, and do not stop it abruptly without advice if it was prescribed for a specific condition like a peptic ulcer or severe reflux. The right step is to tell your oncologist what you are taking and why. They may switch you to a different type of acid medicine, adjust the timing, or decide the benefit of continuing outweighs the interaction risk in your situation. An informed decision made with your team is always safer than an unsupported change.

Food does affect the rate and amount of gefitinib absorbed, but through a different mechanism from acid suppression. The prescribing guidance for gefitinib notes it can be taken with or without food, so your oncologist will advise on the routine that works for your situation. The acid-medicine interaction is a more direct and controllable concern. If you are making any change to when or how you take your tablet, tell your team first.

Some Ayurvedic and traditional digestive preparations contain alkaline ingredients that raise the pH of the stomach, which can reduce gefitinib absorption in the same way as a conventional antacid. The interaction data for traditional preparations is thinner than for prescription medicines, which makes this harder to assess precisely. Tell your oncologist the name of the product and how often you take it before continuing — do not assume a traditional preparation is without effect.

Routine blood tests do not measure gefitinib levels in clinical practice, so there is no simple number to check. Response to treatment is assessed through imaging — typically a CT scan — at intervals your oncologist will explain. If an interaction has been reducing absorption throughout, the scan results may not reflect the full potential of the treatment. This is why the interaction needs to be identified and managed from the beginning, not discovered later. Tell your team about every acid medicine now.